воскресенье, 29 января 2017 г.

Pfizer, Inc. (PFE) Lifted to "Hold" at Zacks Investment Research

Pfizer, Inc. (PFE) Lifted to "Hold" at Zacks Investment Research


According to Zacks, "Pfizer has been working on strengthening its product portfolio as well as pipeline through acquisitions and licensing deals. While the Hospira acquisition significantly expanded Pfizer's sterile injectable and biosimilar capabilities, the Medivation deal strengthened its cancer franchise by adding Xtandi to its portfolio.



from Biotech News